Prophylactic IV magnesium is associated with a reduced risk for cisplatin-associated acute kidney injury in patients with ...

Shruti Gupta, MD, MPH, and David Leaf, MD, MMSc, of the Renal Division, Department of Medicine at Brigham and Women's ...

Magnesium IV protects kidneys from cisplatin-induced damage, reducing the risk of acute kidney injury during chemotherapy.

There are currently no proven therapies that reduce cisplatin-induced acute kidney injury (AKI) in patients with cancer.

Shruti Gupta, MD, MPH, and David Leaf, MD, MMSc, of the Renal Division, Department of Medicine at Brigham and Women’s Hospital are the first and senior authors, respectively, of a paper published in ...

Penpulimab is approved for multiple indications in China, but this marks the first US approval for the novel monoclonal ...

Dr. Huang concluded this presentation discussing results of a phase II study of tislelizumab as neoadjuvant treatment for cisplatin-ineligible high-risk upper tract urothelial carcinoma with the ...

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

For combination therapy, the FDA recommends 200 mg of penpulimab-kcqx every 3 weeks. Monotherapy is recommended at 200 mg ...

At a time when other nations are expanding research and development, the U.S. should be strengthening its commitment, not dismantling it.